Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Stock Holdings Decreased by Legal & General Group Plc

Legal & General Group Plc decreased its position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 3.6% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 57,623 shares of the company’s stock after selling 2,156 shares during the period. Legal & General Group Plc owned about 0.06% of Day One Biopharmaceuticals worth $730,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. R Squared Ltd acquired a new position in shares of Day One Biopharmaceuticals in the 4th quarter valued at about $31,000. E Fund Management Co. Ltd. purchased a new stake in shares of Day One Biopharmaceuticals during the fourth quarter worth $143,000. KLP Kapitalforvaltning AS acquired a new position in Day One Biopharmaceuticals in the 4th quarter worth about $150,000. Teacher Retirement System of Texas grew its stake in shares of Day One Biopharmaceuticals by 20.9% in the 4th quarter. Teacher Retirement System of Texas now owns 17,825 shares of the company’s stock valued at $226,000 after buying an additional 3,086 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its stake in Day One Biopharmaceuticals by 11.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 21,383 shares of the company’s stock valued at $271,000 after acquiring an additional 2,180 shares during the last quarter. 87.95% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

DAWN has been the subject of a number of recent research reports. HC Wainwright reiterated a “buy” rating and issued a $36.00 price objective on shares of Day One Biopharmaceuticals in a report on Thursday, April 3rd. The Goldman Sachs Group dropped their price target on shares of Day One Biopharmaceuticals from $39.00 to $27.00 and set a “buy” rating on the stock in a research report on Tuesday, March 25th. Bank of America dropped their target price on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Wedbush reaffirmed an “outperform” rating and issued a $32.00 price target on shares of Day One Biopharmaceuticals in a research report on Wednesday, February 26th. Finally, Needham & Company LLC reissued a “buy” rating and set a $32.00 price objective on shares of Day One Biopharmaceuticals in a research report on Wednesday, February 26th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $32.29.

Day One Biopharmaceuticals Stock Performance

DAWN opened at $7.74 on Tuesday. The stock’s 50 day simple moving average is $8.27 and its 200-day simple moving average is $11.53. The stock has a market cap of $784.48 million, a PE ratio of -7.51 and a beta of -1.24. Day One Biopharmaceuticals, Inc. has a 1 year low of $6.41 and a 1 year high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.34). The firm had revenue of $29.21 million for the quarter, compared to the consensus estimate of $27.11 million. Equities analysts forecast that Day One Biopharmaceuticals, Inc. will post -0.72 earnings per share for the current fiscal year.

Insider Buying and Selling at Day One Biopharmaceuticals

In other news, General Counsel Adam Dubow sold 4,646 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total value of $55,566.16. Following the sale, the general counsel now owns 39,602 shares in the company, valued at approximately $473,639.92. The trade was a 10.50 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Jeremy Bender sold 12,048 shares of the company’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total transaction of $144,094.08. Following the sale, the chief executive officer now directly owns 128,015 shares in the company, valued at $1,531,059.40. This represents a 8.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 21,064 shares of company stock valued at $251,925. 6.20% of the stock is currently owned by corporate insiders.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.